Isis backs GlaxoSmithKline on directors' pay

Isis Asset Management, the £63.5bn (€94.8bn) UK fund manager, will vote in favour of GlaxoSmithKline's executive pay policy at the pharmaceutical group's annual meeting next week.

The decision by Isis, which has taken a tough stance on generous director pay packages, comes as a significant boost for GlaxoSmithKline, which last year became the first UK company to see its remuneration policy voted down by shareholders.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump